List of Stem Cells Companies in Canada - 12

Built on 30+ years of foundational expertise, Allarta’s proprietary platform is designed to overcome immune rejection, prevent cell escape and safely deliver cell and stem cell therapies. Our lead product is a cell therapy focused on type 1 diabetes (T1D) as a first indication.

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of currently incurable diseases. Aspect is creating these next generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body with the aim of treating currently incurable diseases such as type 1 diabetes as well as genetic and acquired liver diseases.

CryoStasis is a biotech company specializing in bio-preservation of cells, tissues and organs. Located in Ottawa and based on 30 years of pioneering research in the Canadian Arctic, we have developed a method that overturns the long-held belief that biological material must be frozen for its function to be preserved. By using rationally designed cryoprotectants (Woolii™Cool media) along with temperature and pressure management systems (Woolii™Pod), our platform drops temperatures well below freezing, halting cellular metabolism WITHOUT TURNING WATER INTO ICE. Maintaining sub-zero, unfrozen conditions induces stasis (indefinite preservation) while avoiding the dramatic loss of cell function, therapeutic potency and manufacturing yield that occur as a result of freeze-thaw damage. CryoStasis works with BioPharma, CDMOs and research institutions to help ensure life-changing cell & gene therapies can be produced at-scale economically, and reach patients whenever / wherever they are needed.

ExCellThera is an advanced clinical-stage company specializing in cell expansion and engineering, providing molecules and bioengineering solutions to expand stem cells.

Hemostemix is a public clinical-stage company that develops and commercializes innovative blood-derived cell therapies for medical conditions that are not adequately addressed by current treatments.

LineaBio's mission is to enable the cell and gene therapy industry by providing access to high-quality, off-the-shelf iPSC lines manufactured under GMP that streamline drug product manufacturing. By allowing therapeutic developers to cut costs and accelerate timelines for GMP reprogramming, LineaBio strives to achieve its vision of making cell therapy universally accessible and affordable. Founded in 2023 by parent companies CCRM and OmniaBio, LineaBio draws on a team of iPSC experts that have been developing an iPSC platform for more than a decade.

Cell and gene therapy promises to one day cure any pathology; Modulari-T’s MARC Platform produces the tools to fulfill that promise.

Morphocell Technologies Inc. is a regenerative medicine company focused on the development and commercialization of stem cell therapies and engineered tissues targeting liver failure. The Company is a spin-off of the Hepatology and Cell Therapy lab of Sainte-Justine University Hospital Center, in Montreal. Founded in April 2018 on the technology developed by Dr.Paganelli, a pediatric transplant hepatologist and stem cell scientist, Morphocell Technologies aims at bringing to market the first effective treatment for acute, chronic and acute-on-chronic liver failure.

Notch is an early-stage biotech company, working to maximize the benefit of cell therapies through a proprietary T cell-production platform which combines sophisticated product design with commercial-compatible processes to enhance patient outcomes. Notch’s iPSC-based technology platform allows for precision control of notch signaling, which removes several critical limiting factors in the development of cell therapies, delivering the ability to design and manufacture a uniform and unlimited supply of therapeutic T cells.

RepliCel Life Sciences Inc. is leading a revolution in the development of products for sports medicine and aesthetics. We are a regenerative medicine company developing innovative, clinical-stage technologies for unparalleled skin rejuvenation, tendon regeneration, and hair regrowth. RepliCel is currently involved in three clinical development programs: RCT-01 for treatment of Achilles tendinosis, RCS-01 for skin rejuvenation, and RCH-01 for treatment of Androgenic Alopecia. In Asia, RCH-01 is the subject of a co-development partnership with cosmetics and skincare giant Shiseido Company, Limited. Shiseido is currently funding a clinical study for the treatment of male and female pattern baldness (androgenic alopecia) in Japan with data anticipated in late 2018. RepliCel's nearest-term commercial asset is its next-generation dermal injector, RCI-02 which represents a medical device bringing unparalleled precision and consistency to dermal injections including shallow, even dispersion of dermal fillers for fine wrinkles. RCI-02 also promises to obviate the need for local anesthetic injections due to its patented skin-numbing element embedded in the device.

Starpax Biopharma Inc. has developed a novel Precision 3D Guidance Therapy of Magnetodrones™ in tumors. Magnetodrones™ are unique medication-bearing bacteria, developed by Starpax™, that are sensitive to magnetic fields. They deliver the medication into the mass of the tumour, without allowing the medication to circulate in the bloodstream. At the same time, the Magnetodrones™ saturate hypoxic areas where cancerous cells are difficult to reach with other treatments. Magnetodrones are injected directly into the tumour and are guided by the PolarTrak device, in which the patient is positioned. The PolarTrak™ prevents the Magnetodrones™ from leaving the tumour and guides them in 3D with special magnetic fields. Starpax Biopharma inc. a développé une thérapie inédite de guidage de précision 3D de Magnétodrones™ dans les tumeurs.. Les Magnétodrones™ sont des bactéries uniques développées par Starpax, sensibles aux champs magnétiques, sur lesquelles sont attachés les médicaments à leur surface. Les Magnétodrones™ distribuent des médicaments dans la masse des tumeurs sans circuler dans le réseau sanguin, tout en saturant les zones hypoxiques où les cellules cancéreuses sont difficiles à atteindre par le biais d'autres traitements. Les Magnétodrones™ sont injectés directement dans la tumeur et guidés par l'appareil PolarTrak™, où le patient est installé. Le PolarTrak™ empêche les Magnétodrones™ de sortir de la tumeur et les guide en 3D grâce à ses champs magnétiques spéciaux.

STEMCELL Technologies is a Canadian biotechnology company that helps power leading-edge life science research around the world. Driven by our love of science and passion for quality, we are Scientists Helping Scientists—standing by our customers to provide the outstanding products, technical support, and training they need to advance their research. Scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research are among those who rely on our cell culture media, cell separation products, instruments, accessory products, and services. Since the launch of the company by Dr. Allen Eaves in 1993, STEMCELL has reinvested all profits back into the research and development of products to better support the international research community. Today, STEMCELL is the largest biotech company in Canada, with over 2000 employees globally, most with scientific or engineering degrees. Through our many regional offices, as well as our distribution centers in Vancouver, Seattle, Grenoble, and Singapore, we deliver our innovative, specialized products to more than 70 countries. At STEMCELL, we are dedicated to improving lives through advancing knowledge and scientific discovery, through our commitment to fostering diversity and inclusion in STEM and the life sciences industry, and through our investments in sustainability, community, and social responsibility. We do all this because we love science as much as you do. #ScientistsHelpingScientists